|
|
 |
|
Viewing report
|
|
|
|
U.S. Pharmacogenomics Markets
Frost & Sullivan, July 2001
Pharmacogenomics Pave the Way for Genetically Tailored Drugs
The identification of the human genome's chain sequence is revolutionizing the biotechnology and pharmaceuticals industries. Pharmacogenomics analyzes how an individual's genetic inheritance affects the body's variable response to drugs. By understanding each patient at such a profound level, pharmaceutical
manufacturers will eventually be able to produce personalized drugs that meet the unique needs of an individual's genetic makeup. Tailor-made medicines
could all but eliminate harmful drug interactions while enhancing drug efficacy, safety, and improving patients' treatments.
The field of pharmacogenomics targets specific genes for therapeutics, as well as screens genes for potential drug interactions, aiding pharmaceuticals in the
development of highly sophisticated medications. This study assesses the future of markets for genetic services (such as genetic screening), gene-based
diagnostics, and drug development for rare genetic diseases. With this in-depth research at your fingertips, your company will be poised to capitalize
on a burgeoning field.
Key Alliances and Pro-active Networking Efforts Essential for Success
Investors and established companies should begin scouting start-up companies and academic laboratories for innovative technologies, says the study's author. Forging alliances with universities' technology transfer offices, teaching hospitals, and large research institutions are crucial for market expansion.
At the same time, it is essential for participants to attend industry organization conferences to network with financial supporters of this field. Companies need to be visible and promote themselves as advocates of new
ventures, says the author. This study highlights industry challenges and offers strategic recommendations to help maximize your revenue-generating potential.
Overseas Markets Hold Promise for Orphan Drugs
Stringent healthcare regulations in foreign countries can make it difficult for pharmaceutical companies to introduce new products overseas. As the author states, The 'orphan' designation, which applies to a very select population of patients, may be an exception to the rule.
However, orphan drugs, which treat rare genetic diseases affecting tiny populations, could meet lower market barriers. It is conceivable that a wider
interpretation of compassionate use could apply to 'orphan' drugs, says the author. This analysis surveys laws that will impact the development of the field, helping you anticipate and overcome obstacles that might lie ahead.
Customers who bought this item also bought
Pharmacogenomics for Clinical Use and in Drug Development
Understanding Pharmacogenomics
Orphan Drug Strategies
The Role of Pharmacogenomics in Personalized Medicine
How to Get Ahead with Pharmacogenomics
Orphan Drugs Pipeline Analysis: Wider Incentives Encourage Orphan Drug R&D
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
The Pharmacogenomics Outlook
Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2009
Impact of Pharmacogenomics on Public Healthcare Policy: Educating Patients, Payors and Healthcare Providers
Orphan Disease Series - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market?
Genetic Diseases and Pharmacogenomics
|
|
|
|
